Τόμος 35 (2021) – Τεύχος 3 –Άρθρο 4 – Review of Clinical Pharmacology and Pharmacokinetics – Διεθνής Έκδοση – Volume 35 (2021) – Issue 3 – Article 4 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

By | | Πλήρες Κείμενο στα Αγγλικά - Full Text in English
Τίτλος – Title

Comparing influenza and COVID-19 infections

Συγγραφέας – Author

Chrysoula Taskou, Christina Nanou, Aikaterini Lykeridou

General Hospital “Alexandra”, Athens, Greece
Department of Midwifery, University of West Attica (UniWA), Aigaleo, Greece
Παραπομπή – Citation

C. Taskou, C. Nanou, A. Lykeridou.Comparing influenza and COVID-19 infections.  Review Clin. Pharmacol. Pharmacokinet. 2021, 35, 3, 111-115
Ημερομηνία Δημοσιευσης – Publication Date
20-11-2021
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά – English
Λέξεις κλειδιά – Keywords
influenza, coronavirus disease 2019, pandemic, viral specificity, risk group, vaccination
Λοιποί Όροι – Other Terms

Μελέτη
Study
Περίληψη – Summary
 Influenza viruses and SARS-CoV-2 both infect the human respiratory system. According to prevalent data, in either case, the infection can be serious and can even sometimes lead to death. However, many cases might show no symptoms at all. The viruses that cause influenza and COVID-19 infections are different. The new coronavirus, SARS-CoV-2, is re-sponsible for COVID-19 infection. The scope of this study was to clarify the differences and similarities between the two infections to help manage the pan-demic as successfully as possible. The Medline, Google scholar, Cochrane Library and Scopus data-bases were searched for relevant articles published through March 2021, with no limitation on publication date. It has now been one year of pandemic period since the break out of COVID-19 infection last year. Studies have shown that the SARS-CoV-2 virus spreads easier and quicker, and has been associated with far more serious symptoms and complications in comparison with influenza viruses. Because of the common symptoms, which are identified between the two infections and the fact that research on vaccina-tion against COVID-19 infection remains incomplete, obscures the management of the pandemic.
Αναφορές – References 1. Nakatsu S., Murakami S., Shindo K., Horimoto T., Sagara H., Noda T., Kawaoka Y.: Influenza C and D Viruses Package Eight Organized Ribonucleopro-tein Complexes. J. Virol. 92(6): e02084-17 (2018). doi: 10.1128/JVI.02084-17.
2. Bouvier N.M., Palese P.: The biology of influenza viruses. Vaccine. 26 Suppl 4(Suppl 4): D49–53 (2008). doi: 10.1016/j.vaccine.2008.07.039.
3. Fehr A.R., Perlman S.: Coronaviruses: an over-view of their replication and pathogenesis. Methods Mol. Biol. 1282: 1-23 (2015). doi: 10.1007/978-1-4939-2438-7_1.
4. World Health Organization: Novel Coronavirus (2019-nCoV), Situation Report-12 (2020).
5. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., Zhou H., Hu Z., Zhou W., Zhao L., Chen J., Meng Y., Wang J., Lin Y., Yuan J., Xie Z., Ma J., Liu W.J., Wang D., Xu W., Holmes E.C., Gao G.F., Wu G., Chen W., Shi W., Tan W.: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus ori-gins and receptor binding. Lancet. 395(10224): 565–574 (2020). doi: 10.1016/S0140-6736(20)30251-8.
6. Brian D.A., Baric R.S.: Coronavirus genome structure and replication. Curr. Topics Microbiol. Immunol. 287: 1–30 (2005). doi: 10.1007/3-540-26765-4_1.
7. Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I.: Insights into SARS-CoV-2 ge-nome, structure, evolution, pathogenesis and ther-apies: Structural genomics approach. Biochim. Bio-phys. Acta Mol. Basis Dis. 1866(10): 165878 (2020). doi: 10.1016/j.bbadis.2020.165878.
8. Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z., Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.: Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. 10(7): 1228-1238 (2020). doi: 10.1016/j.apsb.2020.04.009.
9. Alhalaili B., Popescu I.N., Kamoun O., Alzubi F., Alawadhia S., Vidu R.: Nanobiosensors for the De-tection of Novel Coronavirus 2019-nCoV and Other Pandemic/Epidemic Respiratory Viruses: A Review. Sensors (Basel). 20(22): 6591 (2020). doi: 10.3390/s20226591.
10. Zou L., Ruan F., Huang M., Liang L., Huang H., Hong Z., Yu J., Kang M., Song Y., Xia J., Guo Q., Song T., He J., Yen H.L., Peiris M., Wu J.: SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382(12): 1177–1179 (2020). doi: 10.1056/NEJMc2001737.
11. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L.: Epidemiological and clinical characteristics of 99 cases of 2019 novel corona-virus pneumonia in Wuhan, China: a descriptive study. Lancet. 395(10223): 507-513 (2020). doi: 10.1016/S0140-6736(20)30211-7.
12. Hellewell J., Abbott S., Gimma A., Bosse N.I., Jarvis C.I., Russell T.W., Munday J.D., Kucharski A.J., Edmunds W.J.: Feasibility of controlling COVID-19 outbreaks by isolation of cases and con-tacts. Lancet Glob. Health. 8(4): e488–e496 (2020). doi: 10.1016/S2214-109X (20)30074-7.
13. Esposito S., Principi N.:. Multisystem Inflamma-tory Syndrome in Children Related to SARS-CoV-2. Paediatr. Drugs. 23(2): 119-129 (2021). doi: 10.1007/s40272-020-00435-x.
14. Franco-Moreno A., Piniella-Ruiz E., Montoya-Adarraga J., Ballano-Franco C., Alvarez-Miguel F., Peinado-Martinez C., Landete-Hernandez E., Saez-Vaquero T., Ulla-Anes M., Torres-Macho J.: Portal vein thrombosis in a patient with COVID-19. Thromb. Res. 194: 150–152 (2020). doi: 10.1016/j.thromres.2020.06.019.
15. Levi M., Thachil J., Iba T., Levy J.H.: Coagula-tion abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 7(6): e438–e440 (2020). doi: 10.1016/S2352-3026(20)30145-9.
16. Beigel J.H., Tomashek K.M., Dodd L.E.: Remdesivir for the treatment of Covid-19—preliminary report. Reply N Engl J Med. 383(10): 994 (2020). doi: 10.1056/NEJMc2022236.
17. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., Lopez de Castilla D., Finberg R.W., Dierberg K., Tapson V., Hsieh L., Patterson T.F., Paredes R., Sweeney D.A., Short W.R., Touloumi G., Lye D.C., Ohmagari N., Oh M.D., Ruiz-Palacios G.M., Benfield T., Fätkenheuer G., Kortepeter M.G., Atmar R.L., Creech C.B., Lundgren J., Babiker A.G., Pett S., Neaton J.D., Burgess T.H., Bonnett T., Green M., Makowski M., Osinusi A., Nayak S., Lane H.C.; ACTT-1 Study Group Mem-bers: Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 383(19): 1813-1826 (2020). doi: 10.1056/NEJMoa2007764.
18. Burwick R.M., Yawetz S., Stephenson K.E., Col-lier A.Y., Sen P., Blackburn B.G., Kojic E.M., Hirsh-berg A., Suarez J.F., Sobieszczyk M.E., Marks K.M., Mazur S., Big C., Manuel O., Morlin G., Rose S.J., Naqvi M., Goldfarb I.T., DeZure A., Telep L., Tan S.K., Zhao Y., Hahambis T., Hindman J., Chokka-lingam A.P., Carter C., Das M., Osinusi A.O., Brainard D.M., Varughese T.A., Kovalenko O., Sims M.D., Desai S., Swamy G., Sheffield J.S., Zash R., Short W.R.: Compassionate use of remdesivir in pregnant women with severe COVID-19. Clin. Infect. Dis. ciaa1466 (2020). doi: 10.1093/cid/ciaa1466.
19. National Institutes of Health (NIH): Final report confirms remdesivir benefits for COVID-19. (2020) https://www.ncbi.nlm.nih.gov/search/research-news/11717/.
20. Center Of Disease Control and Prevention (CDC): Key Facts About Seasonal Flu Vaccine. (2020) https://www.cdc.gov/flu/prevent/keyfacts.htm.
21. Ophinni Y., Hasibuan A.S., Widhani A., Maria S., Koesnoe S., Yunihastuti E., Karjadi T.H., Reng-ganis I., Djauzi S.: COVID-19 Vaccines: Current Status and Implication for Use in Indonesia. Acta Medica Indonesiana. 52(4): 388-412 (2020).
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6583

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Τι είναι η Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Review of Clinical Pharmacology and Pharmacokinetics-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση
Articles Published in Review of Clinical Pharmacology and Pharmacokinetics-International Edition

Συντακτικη Επιτροπή-Editorial Board

Bookmark the permalink.

Comments are closed.